Ephraim Vidal, Ph.D.

Ephraim Vidal, Ph.D. has extensive work experience in the pharmaceutical industry. Most recently, they serve as the Vice President of CMC Technical Operations at Aeovian Pharmaceuticals, starting in June 2021. Prior to this, they worked as a Director at Mirati Therapeutics from July 2020 to June 2021. From 2015 to 2020, they held the role of Associate Director at Bristol-Myers Squibb, where they managed small molecule active pharmaceutical ingredient (API) contract manufacturers and oversaw optimization, technical transfers, and process validation.

Before joining Bristol-Myers Squibb, Ephraim was a Senior Manager at Codexis, Inc. in 2014. Ephraim also gained experience as an API Development Scientist II at Hospira from 2011 to 2014, where they were responsible for designing, developing, optimizing, and scaling up chemical processes for manufacturing active pharmaceutical ingredients.

In addition, Ephraim worked as a Temporary Senior Scientist at Vertex Pharmaceuticals in 2011 and as a Principal Research Investigator at sanofi-aventis from 2001 to 2011.

Ephraim Vidal, Ph.D. has a strong educational background in chemistry. Ephraim obtained their Ph.D. in Chemistry from Stony Brook University and further pursued their studies as a Postdoctoral Fellow in Synthetic Organic Chemistry at the Memorial Sloan-Kettering Cancer Center. Following that, they continued their academic journey at Stony Brook University, where they served as a Postdoctoral Lecturer and Postdoctoral Research Associate, focusing on Synthetic Organic Chemistry and Catalysis.